- Home
- SOR vs NBP Comparison
SOR vs NBP Comparison
Compare SOR & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOR | NBP |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | 32 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.5M | 379.3M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | SOR | NBP |
|---|---|---|
| Price | $46.91 | $3.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 11.7K | ★ 608.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.66 | $3.03 |
| 52 Week High | $50.41 | $5.19 |
Technical Indicators
Market Signals| Indicator | SOR | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 41.49 | 43.53 |
| Support Level | $45.92 | $3.04 |
| Resistance Level | $50.05 | $3.74 |
| Average True Range (ATR) | 1.11 | 0.27 |
| MACD | -0.17 | 0.02 |
| Stochastic Oscillator | 31.63 | 21.69 |
Price Performance
Historical ComparisonAbout SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.